Oncoclinicas do Brasil (ONCO3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncoclinicas do Brasil (ONCO3) has a cash flow conversion efficiency ratio of 0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$151.75 Million ≈ $29.78 Million USD) by net assets (R$1.20 Billion ≈ $235.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check how strategically is Oncoclinicas do Brasil's equity deployed to assess the company's strategic physical and investment asset allocation.
Oncoclinicas do Brasil - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Oncoclinicas do Brasil's cash flow conversion efficiency has evolved over time, based on yearly financial data. See shareholders equity of Oncoclinicas do Brasil for net asset value and shareholders' equity analysis.
Oncoclinicas do Brasil Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncoclinicas do Brasil ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
0.168x |
|
Humasis Co. Ltd
KQ:205470
|
0.036x |
|
WITHSECURE
HE:WITH
|
0.022x |
|
CyberTAN Technology Inc
TW:3062
|
-0.071x |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
0.127x |
|
Korea Environment Technology Co. LTD
KQ:029960
|
0.041x |
|
Bus Online Co Ltd
SHE:002188
|
-0.077x |
|
Cybin Inc
NEO:CYBN
|
-0.117x |
Annual Cash Flow Conversion Efficiency for Oncoclinicas do Brasil (2013–2024)
The table below shows the annual cash flow conversion efficiency of Oncoclinicas do Brasil from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Oncoclinicas do Brasil (ONCO3) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | R$3.38 Billion ≈ $663.69 Million |
R$-184.85 Million ≈ $-36.27 Million |
-0.055x | -183.98% |
| 2023-12-31 | R$2.68 Billion ≈ $525.74 Million |
R$-51.56 Million ≈ $-10.12 Million |
-0.019x | +81.35% |
| 2022-12-31 | R$2.63 Billion ≈ $516.54 Million |
R$-271.64 Million ≈ $-53.30 Million |
-0.103x | -2462.19% |
| 2021-12-31 | R$2.30 Billion ≈ $452.27 Million |
R$-9.28 Million ≈ $-1.82 Million |
-0.004x | -102.81% |
| 2020-12-31 | R$681.17 Million ≈ $133.66 Million |
R$97.56 Million ≈ $19.14 Million |
0.143x | -3.16% |
| 2019-12-31 | R$656.37 Million ≈ $128.79 Million |
R$97.08 Million ≈ $19.05 Million |
0.148x | +78.93% |
| 2018-12-31 | R$470.12 Million ≈ $92.25 Million |
R$38.86 Million ≈ $7.62 Million |
0.083x | -85.80% |
| 2017-12-31 | R$232.44 Million ≈ $45.61 Million |
R$135.26 Million ≈ $26.54 Million |
0.582x | +787.30% |
| 2016-12-31 | R$244.56 Million ≈ $47.99 Million |
R$-20.71 Million ≈ $-4.06 Million |
-0.085x | -435.49% |
| 2015-12-31 | R$195.87 Million ≈ $38.43 Million |
R$-3.10 Million ≈ $-607.69K |
-0.016x | -103.88% |
| 2014-12-31 | R$22.77 Million ≈ $4.47 Million |
R$9.29 Million ≈ $1.82 Million |
0.408x | +167.53% |
| 2013-12-31 | R$48.16 Million ≈ $9.45 Million |
R$7.34 Million ≈ $1.44 Million |
0.152x | -- |
About Oncoclinicas do Brasil
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, ch… Read more